Navigation Links
BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
Date:5/20/2008

in estimates that PEG-PAL could be a potential treatment option for a significant portion of the PKU population.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its product candidate PEG-PAL, and expectations regarding filings with regulatory agencies. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results of current and planned clinical trials re
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. BioMarin Announces FDA Approval for Kuvan
2. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Go Healthy Initiates Additional Clinical Tests on Cholesterade
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
8. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
9. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
10. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
11. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...and, January 7 Circassia Ltd, a sp...rgy and critical care, today,announced that follo...with,its ToleroMune(R) anti-allergy technology, t...for a further phase II clinical trial in cat aller...ecruited 120 patients with confirmed,cat allergie...
(Date:1/6/2009)... The Michael J. Fox Fou...our industry research teams for pre-clinical resea...sease. , , The funding was awarded under the Fo...This program, first launched in 2006, supports and...research. TDI is part of MJFF,s focus on ,de-r...
(Date:1/6/2009)...e, January 6 , - ...boration Until,December 2011 , - Expansion...body,Discovery in Ophthalmology , - Revise...rgan,Sublicenses to a Third Party , Exon...d a reinforcement,of its existing drug discovery ...
(Date:1/3/2009)... , , ROSEMONT, Ill., Jan. 2 /PRNewswire-USN...growing technology providing an increasing number ...f back pain according to an article in the January... of Orthopaedic Surgeons ( http://www.jaaos.org/ )...s, additional technical developments will allow MR...
Breaking Medicine Technology:Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3Roche completes acquisition of ARIUS 7890 1Roche completes acquisition of ARIUS 7890 2Connecticut State Medical Society and Genomas Co Sponsor Forum on DNA Guided Medicine and the Path to Personalized Health Care 7888 1Connecticut State Medical Society and Genomas Co Sponsor Forum on DNA Guided Medicine and the Path to Personalized Health Care 7888 2Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 1Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 2Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 3Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 4World Alzheimer 26apos 3Bs Day 2008 Special Report 3A New Alzheimer Targets Take Center Stage 26688 1World Alzheimer 26apos 3Bs Day 2008 Special Report 3A New Alzheimer Targets Take Center Stage 26688 2
... - Journal Article Also Demonstrates the Promise o...ibiotics -, PALO ALTO, Calif., June 21, 2007 /PRNe...d pharmaceutical company, announced,today that the...that details how AN2690, the company,s lead clinic...th synthesis of a specific,protein required for fu...
... FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - N...ublication in the June 23 issue,of the journal The...ne therapy trial for Parkinson,s disease and the f...,s own brain cells for any adult,neurodegenerative... in 12 patients with,advanced Parkinson,s disease ...
Other Medicine Technology:Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,AN2690; Findings Published in Science 2Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,AN2690; Findings Published in Science 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6
(Date:1/8/2009)...s are available that work, CDC officials stress ,...he most common strain of flu this season is resist...ernment health officials said Thursday there is no...n so far has been slow, and that other drugs work ... officials adopting a watchful attitude for now. ,...
(Date:1/8/2009)...May Be Revealed Friday, January 9 , , WASHINGT...ice Employees International Union (SEIU) President... International Executive Board to discuss the forc...mbers out of SEIU United Healthcare Workers-West (... final decision until tomorrow. , , According t...
(Date:1/8/2009)...ude study could shape new treatments for secondary...re-USNewswire/ -- Scientists at St. Jude Children,...tive treatment for bacterial pneumonia following i...cin and azithromycin, which kill bacteria by inhib...than a standard first-line treatment with the "bet...
(Date:1/8/2009)...Jude Children,s Research Hospital have demonstrate...ia following influenza. They found that the antibi...teria by inhibiting their protein synthesis, are m... with the "beta-lactam" antibiotic ampicillin, whi...e finding is important because pneumonia, rather t...
Breaking Medicine News(10 mins):Health News:Common Flu Strain Resistant to Popular Antiviral Drug 2Health News:Common Flu Strain Resistant to Popular Antiviral Drug 3Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3
...sk of having a premature baby is up for women who ... cervix to eliminate precancerous cells, called LE...University revealed. After conducting a study in...hat nearly 1,500 premature births could have been ...
...ood - quick, convenient and cheap, which, we all k...ble cheeseburger costs less than a head of lettuce...es are one of the keys to good health; Barbara Rol...t encouraging people to eat large quantities of lo...
...rt published by the U.S. Centers for Disease Contr...is becoming widespread and aggressive among teenag...on pattern of excessive alcohol use" and the Natio...olism defines binge drinking as a pattern of drink...
...chers, in the first study of its kind, have comput...d found they are less prone to harm than collegiat...rs at Rhode Island Hospital and Brown Medical Scho...ished in the January 2007 issue of the American Jo...
Other Medicine News:Health News:Surfing Safer Than Soccer: Study 2Health News:Surfing Safer Than Soccer: Study 3
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: